Enliven (ELVN) Therapeutics announced the appointment of Rick Fair as Chief Executive Officer and member of the Board of Directors of Enliven, effective December 11, 2025. Sam Kintz, Co-Founder and former Chief Executive Officer of Enliven, will assume a new role as Head of Pipeline, also effective December 11, 2025. The transition plan reflects Enliven’s commitment to the next phase of the Company, including a Phase 3 trial for ELVN-001 in patients with chronic myeloid leukemia, CML, and its commercialization. Fair most recently served as President and Chief Executive Officer of Bellicum Pharmaceuticals
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating
- Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating
- Enliven Therapeutics Reports Q3 2025 Financial Results
- Promising Future for Enliven Therapeutics: Buy Rating Backed by Strong Phase 1 Data and Financial Stability
- Enliven reports Q3 EPS (32c) vs. (48c) last year